- Home
- BIIB vs GIB Comparison
BIIB vs GIB Comparison
Compare BIIB & GIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- GIB
- Stock Information
- Founded
- BIIB 1978
- GIB 1976
- Country
- BIIB United States
- GIB Canada
- Employees
- BIIB N/A
- GIB N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- GIB Professional Services
- Sector
- BIIB Health Care
- GIB Consumer Discretionary
- Exchange
- BIIB Nasdaq
- GIB Nasdaq
- Market Cap
- BIIB 18.8B
- GIB 24.2B
- IPO Year
- BIIB 1991
- GIB N/A
- Fundamental
- Price
- BIIB $135.28
- GIB $103.74
- Analyst Decision
- BIIB Buy
- GIB Buy
- Analyst Count
- BIIB 27
- GIB 4
- Target Price
- BIIB $188.17
- GIB $156.75
- AVG Volume (30 Days)
- BIIB 1.2M
- GIB 234.0K
- Earning Date
- BIIB 07-31-2025
- GIB 07-30-2025
- Dividend Yield
- BIIB N/A
- GIB 0.31%
- EPS Growth
- BIIB 26.39
- GIB 8.72
- EPS
- BIIB 10.12
- GIB 5.30
- Revenue
- BIIB $9,816,400,000.00
- GIB $10,533,984,064.00
- Revenue This Year
- BIIB N/A
- GIB $11.12
- Revenue Next Year
- BIIB N/A
- GIB $4.86
- P/E Ratio
- BIIB $13.29
- GIB $19.51
- Revenue Growth
- BIIB 1.59
- GIB 4.60
- 52 Week Low
- BIIB $110.04
- GIB $92.85
- 52 Week High
- BIIB $238.00
- GIB $122.79
- Technical
- Relative Strength Index (RSI)
- BIIB 61.69
- GIB 41.74
- Support Level
- BIIB $129.08
- GIB $103.21
- Resistance Level
- BIIB $134.75
- GIB $106.45
- Average True Range (ATR)
- BIIB 3.74
- GIB 1.59
- MACD
- BIIB 0.65
- GIB -0.23
- Stochastic Oscillator
- BIIB 82.50
- GIB 23.36
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About GIB CGI Inc.
CGI is a Canada-based IT-services provider with an embedded position in North America and Europe. The company generates more than CAD 14 billion in annual revenue, employs over 90,000 personnel, and operates across 400 offices in 40 countries. CGI offers a broad portfolio of services such as consulting, systems integration, application maintenance, and business process services. Its largest vertical market is government, which contributes more than a third of group revenue.